Cogent Biosciences
Signal active
Organization
Contact Information
Overview
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its antibody-coupled T-cell receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2014
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Cogent Biosciences headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $146.8B in funding across 160 round(s). With a team of 101-250 employees, Cogent Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cogent Biosciences, raised $12.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
10
Investors
4
Lead Investors
0
Total Funding Amount
$917.7M
Details
2
Cogent Biosciences has raised a total of $917.7M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2015 | Early Stage Venture | 65.0M | ||
| 2014 | Early Stage Venture | 12.3M |
Investors
Cogent Biosciences is funded by 37 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cogent Biosciences | - | FUNDING ROUND - Cogent Biosciences | 12.3M |
| F-Prime Capital | - | FUNDING ROUND - F-Prime Capital | 12.3M |
| Cogent Biosciences | - | FUNDING ROUND - Cogent Biosciences | 12.3M |
| Eight Roads Ventures | - | FUNDING ROUND - Eight Roads Ventures | 12.3M |
Recent Activity
There is no recent news or activity for this profile.